Annapolis internal and external medicine physician James “Pin” Calvert said his team is making great progress in treating the parasitic disease strep throat.
The Maryland Institute for Microbiology and Immunology, a research and development facility in the state capital, is making a major leap toward finding a vaccine for the disease.
“We’re in a phase where we’ve actually started getting positive results with the vaccine, and then we’re seeing that a lot of our patients are having better outcomes,” Calvert told TechRadars.
The vaccine has been developed by the MIMI, which is based in Bethesda.
The vaccine is administered through nasal spray, a device Calvert says has been in use for decades.
It has been administered in conjunction with a cocktail of other medications and is administered to patients by a team of physicians.
“It is a very, very safe, easy to administer, very effective, very well tolerated drug,” Calvert said.
“We don’t have to inject people, but it is very effective.”
While pinworm is a chronic illness that can cause respiratory distress, Calvert believes the drug will provide the best protection against it.
The drug is administered as a nasal spray and can be given for several days before a person develops the symptoms.
“I don’t think it’s that difficult to get this drug into the body,” Calevert said, noting that the only risk with the drug is if someone swallows too much of it.
“The people that have the most success are people that are at the upper end of the spectrum.
We have people who are very, almost, at the extreme,” Calvers said.
Calvert has a particular interest in the potential of the drug to combat strep throats.
He said the disease is one of the most common cancers in Maryland, and there is no cure.
Strep throats are caused by parasites that attach themselves to the throat, which causes it to swell and leak mucus.
Calvers team believes the vaccine is the answer to the problem, as it prevents the parasites from attaching themselves.
Calvert is currently testing a new nasal spray that is being manufactured by an Indian company, and the company has started a pilot program with a local hospital.
Calvert’s team is currently in the early stages of testing the nasal spray.
Calvers team is trying to increase the effectiveness of the vaccine by increasing the dose, but he believes that will take a lot longer.
He thinks the drug could be ready to be administered as early as next year.
“The more the good comes out, the more we can keep up with it.
But right now, it’s just a matter of time.
It’s about getting the right numbers out there, and getting the people who have the best outcomes to see them first,” Calmert said of his team.